CN113121640B - Crystal of monomethyl auristatin E and preparation method thereof - Google Patents
Crystal of monomethyl auristatin E and preparation method thereof Download PDFInfo
- Publication number
- CN113121640B CN113121640B CN202110239973.0A CN202110239973A CN113121640B CN 113121640 B CN113121640 B CN 113121640B CN 202110239973 A CN202110239973 A CN 202110239973A CN 113121640 B CN113121640 B CN 113121640B
- Authority
- CN
- China
- Prior art keywords
- degrees
- solvent
- formula
- compound
- mixed system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 47
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 title abstract description 61
- 108010093470 monomethyl auristatin E Proteins 0.000 title description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 10
- 239000002904 solvent Substances 0.000 claims description 55
- 150000001875 compounds Chemical class 0.000 claims description 47
- 238000003756 stirring Methods 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 33
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical group CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical group CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 24
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical group COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 14
- 239000007787 solid Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 8
- TZIHFWKZFHZASV-UHFFFAOYSA-N methyl formate Chemical group COC=O TZIHFWKZFHZASV-UHFFFAOYSA-N 0.000 claims description 8
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 4
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 4
- 229940011051 isopropyl acetate Drugs 0.000 claims description 4
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 4
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 4
- 229940090181 propyl acetate Drugs 0.000 claims description 4
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims 2
- 239000011259 mixed solution Substances 0.000 claims 1
- -1 methyl auristatin E Chemical compound 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000003860 storage Methods 0.000 abstract description 3
- 230000003321 amplification Effects 0.000 abstract description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 230000007547 defect Effects 0.000 abstract description 2
- 238000009826 distribution Methods 0.000 abstract description 2
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 2
- 239000002245 particle Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 239000000562 conjugate Substances 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 239000000611 antibody drug conjugate Substances 0.000 description 9
- 229940049595 antibody-drug conjugate Drugs 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101710112752 Cytotoxin Proteins 0.000 description 5
- 238000003869 coulometry Methods 0.000 description 5
- 231100000599 cytotoxic agent Toxicity 0.000 description 5
- 239000002619 cytotoxin Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000002447 crystallographic data Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002386 leaching Methods 0.000 description 2
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 238000002076 thermal analysis method Methods 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 1
- 102100037709 Desmocollin-3 Human genes 0.000 description 1
- 101000968042 Homo sapiens Desmocollin-2 Proteins 0.000 description 1
- 101000880960 Homo sapiens Desmocollin-3 Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 230000001946 anti-microtubular Effects 0.000 description 1
- 230000002927 anti-mitotic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229940043232 butyl acetate Drugs 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical class COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 239000000878 small molecule-drug conjugate Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a methyl auristatin E crystal form A, a preparation method thereof, a pharmaceutical composition containing the crystal form A and application of the crystal form A in preparation of a pharmaceutical conjugate. The crystal form A has high purity, good stability and low hygroscopicity, is particularly suitable for industrial application, and overcomes the defects of low purity, poor stability, unsuitability for storage, high requirement on reaction equipment, complex operation and the like when amorphous MMAE is used for preparing a conjugate in the prior art; secondly, the preparation method of the MMAE crystal form A provided by the invention is simple to operate, the prepared crystal form is high in purity and uniform in particle size distribution, the production cost is reduced, and the preparation method is suitable for commercial production amplification.
Description
Technical Field
The invention belongs to the technical field of medicinal chemistry, and particularly relates to a methyl auristatin E crystal, a preparation method thereof, a medicinal composition containing the crystal, and application of the crystal forms in preparation of a medicinal conjugate.
Background
Methyl auristatin E (MMAE, structural formula is shown in formula (I)) is a synthetic derivative of palmatine 10, has very effective antimitotic effect, and can inhibit cell division by blocking polymerization of tubulin to realize antitumor purpose. Is as antimicrotubule like vinblastine, but is approximately 200 times as toxic as vinblastine. Because of the toxicity, it is too toxic to be used by direct intravenous drip, and therefore it can only exert its killing power in drug conjugates (ADC drugs). Among the ADC drugs that have been marketed so far, there are Bentuximab developed by Seattle Genetics, pontotuzumab developed by Genentech, and Ennocumab developed by Seattle Genetics and Astellas in combination, all of which use MMAE as a cytotoxin. At present, in ADC (antibody drug conjugate) and PDC (polypeptide drug conjugate) drugs, MMAE is used as cytotoxin for research.
However, currently commercially available monomethyl auristatin E is an amorphous solid, and no reports have been made on free monomethyl auristatin E crystals in any literature or patent. Amorphous MMAE is easy to deliquesce and poor in stability, and is not beneficial to long-term storage; in addition, amorphous MMAE also has the problem of low purity, resulting in more impurities in the drug conjugate prepared by using amorphous MMAE, difficult subsequent purification, and influence on the safety and effectiveness of the drug conjugate.
Purification methods using reverse phase liquid phase preparation in US2015/23989 and CN109200291A for MMAE purification have low yield, complex operation and high cost.
Therefore, the development of the MMAE crystal form which has good stability and high purity and is suitable for industrial application has very important significance.
Disclosure of Invention
In order to solve the above problems of the prior art, it is an object of the present invention to provide a high purity crystalline form of MMAE having a structure as shown in formula (I) and a method for preparing the same.
Firstly, the invention provides a new crystal form of MMAE, which is named as a crystal form A; specifically, the invention provides a crystal form A of a compound shown as a formula (I), wherein an X-ray powder diffraction pattern of the crystal form A has characteristic peaks at 2theta values of 3.8 degrees +/-0.2 degrees, 9.3 degrees +/-0.2 degrees, 9.9 degrees +/-0.2 degrees and 13.2 degrees +/-0.2 degrees,
further preferably, the X-ray powder diffraction pattern of form a also has diffraction peaks at one or more of 2 Θ values of 10.8 ° ± 0.2 °, 11.9 ° ± 0.2 °, 15.3 ° ± 0.2 ° and 16.3 ° ± 0.2 °, more preferably the X-ray powder diffraction pattern of form a also has diffraction peaks at one or two or three or four of 2 Θ values of 10.8 ° ± 0.2 °, 11.9 ° ± 0.2 °, 15.3 ° ± 0.2 ° and 16.3 ° ± 0.2 °.
Further, the X-ray powder diffraction pattern of the crystalline form a of the compound represented by the formula (I) has diffraction peaks at 2 θ values of 10.8 ° ± 0.2 °, 11.9 ° ± 0.2 °, 15.3 ° ± 0.2 ° and 16.3 ° ± 0.2 °.
Furthermore, the compound shown in the formula (I) in the invention has a crystal form A, and the X-ray powder diffraction pattern of the crystal form A has a 2theta value: characteristic diffraction peaks are provided at 3.8 degrees +/-0.2 degrees, 9.3 degrees +/-0.2 degrees, 9.9 degrees +/-0.2 degrees, 10.8 degrees +/-0.2 degrees, 11.9 degrees +/-0.2 degrees, 13.2 degrees +/-0.2 degrees, 15.1 degrees +/-0.2 degrees, 15.3 degrees +/-0.2 degrees, 16.3 degrees +/-0.2 degrees, 18.4 degrees +/-0.2 degrees, 18.6 degrees +/-0.2 degrees, 20.1 degrees +/-0.2 degrees, 21.6 degrees +/-0.2 degrees and 23.0 degrees +/-0.2 degrees.
According to a particular and preferred aspect of the present invention, said compound of formula (I) in crystalline form a has substantially the same X-ray powder diffraction pattern as shown in figure 1 or 2. Further, the X-ray powder diffraction pattern shows at least 14 diffraction peaks whose positions and intensities are shown in FIG. 1 or 2, in which the peak positions are varied within. + -. 0.2 ℃ and the peak intensities are appropriately varied depending on the specific detection conditions.
Preferably, the compound of formula (I) has a Differential Scanning Calorimetry (DSC) pattern with an endothermic peak at 112.81 ℃ + -2 ℃, wherein the DSC pattern is shown in figure 3.
Further, the crystal form A of the compound shown in the formula (I) contains 0-5% (w/w) of water; preferably, said form a contains 1-3% (w/w) water.
In a second aspect of the invention, there is provided a process for the preparation of form a of the compound of formula (I) comprising the steps of:
a) Adding a compound shown in a formula (I) into a first solvent, stirring for dissolving, and optionally adding water to obtain a first mixed system;
b) Stirring the first mixed system, and then adding a second solvent into the first mixed system to obtain a second mixed system; preferably, the stirring of the first mixed system is carried out at a temperature of-10 to 10 ℃;
c) Stirring the second mixed system, and then adding a third solvent into the second mixed system to obtain a third mixed system; preferably, the stirring of the second mixed system is carried out at a temperature of-10 to 10 ℃;
d) Stirring the third mixed system to separate out solid, thus obtaining the solid; preferably, the stirring of the third mixing system is carried out at a temperature of-10 to 10 ℃.
In the above method, preferably, the first solvent of step a) is selected from esters, isopropanol, DMF or any combination thereof; more preferably, the esters comprise methyl formate, methyl acetate, isopropyl acetate, ethyl acetate, propyl acetate, butyl acetate, or any combination thereof.
Step B) the second solvent is selected from diethyl ether, isopropyl ether, methyl tert-butyl ether, toluene or any combination thereof;
step C) the third solvent is selected from petroleum ether, n-hexane, cyclohexane, methylcyclohexane, n-heptane or any combination thereof.
Further, in the above method, the content of water in the step a) is 0.5 to 4% (w/w) based on the total amount of the first mixed system; preferably, the water content is 1% to 2% (w/w); more preferably the water content is 1-1.5% (w/w); preferably, for example, the water content is 1.1% (w/w), 1.2% (w/w), 1.3% (w/w), 1.4% (w/w), 1.5% (w/w), 1.6% (w/w), 1.7% (w/w), 1.8% (w/w), 1.9% (w/w), or 2% (w/w).
The volume ratio of the first solvent to the second solvent to the third solvent is 1 to 2; more preferably, the volume ratio of the first solvent to the second solvent to the third solvent is 1. In a specific preferred embodiment, the volume ratio of the first solvent to the second solvent to the third solvent is 1.
Further, the feeding ratio of the compound shown in the formula (I) to the first solvent is 1; more preferably, the feeding ratio of the compound represented by the formula (I) to the first solvent is 1.
Further, in the above method, preferably, the first mixed system is stirred in step B), the seed crystal is added to the first mixed system, the temperature is reduced to-10 to 10 ℃, and then the second solvent is added to obtain the second mixed system. In another more preferred embodiment of the present invention, there is provided a process for the preparation of form a of the compound of formula (I) comprising the steps of:
a) Adding a compound shown as a formula (I) into a first solvent, stirring and dissolving, and optionally adding water to obtain a first mixed system; wherein, calculated by the total amount of the first mixed system, the water content is 0.5-4% (w/w), and the feeding ratio of the compound shown in the formula (I) to the first solvent is 1;
b) Stirring the first mixed system, adding seed crystals, continuously stirring at-10 ℃, and then adding a second solvent to obtain a second mixed system; preferably, the volume ratio of the first solvent to the second solvent is 1;
c) Stirring the mixture at the temperature of between 10 ℃ below zero and 10 ℃, and then adding a third solvent into the second mixed system to obtain a third mixed system; preferably, the volume ratio of the first solvent to the third solvent is 1;
d) Stirring the third mixed system under the condition of stirring at the temperature of between 10 ℃ below zero and 10 ℃ to separate out solids, thus obtaining the solid; preferably, the precipitated solid is filtered, optionally rinsed with a third solvent, and then dried under vacuum to obtain the form a.
In the above process, it is further preferred that the first solvent is selected from methyl formate, methyl acetate, isopropyl acetate, ethyl acetate, propyl acetate, butyl acetate, isopropanol, DMF or any combination thereof;
the second solvent is selected from diethyl ether, isopropyl ether, methyl tert-butyl ether, toluene or any combination thereof;
the third solvent is selected from petroleum ether, n-hexane, cyclohexane, methylcyclohexane, n-heptane, or any combination thereof.
In a third aspect of the present invention, there is also provided a pharmaceutical composition comprising the compound of formula (I) provided herein in crystalline form a and a pharmaceutically acceptable carrier.
Preferably, said pharmaceutical composition contains said crystalline form a in an amount of not less than 85%, preferably not less than 90%, preferably not less than 95%, preferably not less than 99%, preferably not less than 99.5%, preferably not less than 99.9%, preferably not less than 99.99% by weight relative to the total amount of compound of formula (I) present in the composition.
In the fourth aspect of the invention, the invention also provides application of the crystal form A of the compound shown in the formula (I) and application thereof in preparing a drug conjugate. Wherein the drug conjugate comprises an antibody drug conjugate, a polypeptide drug conjugate or a small molecule drug conjugate which takes the crystal form A of the compound shown in the formula (I) as cytotoxin. Such as present-tuximab developed by Seattle Genetics, polotuzumab developed by Genentech, and enrobiumab developed in combination with Seattle Genetics and Astellas; also included are currently under-developed ADC (antibody drug conjugates) and PDC (polypeptide drug conjugates) drugs with MMAE as the cytotoxin. Methods for preparing ADC (antibody drug conjugate) and PDC (polypeptide drug conjugate) drugs using MMAE as cytotoxin using MMAE are known and have been reported in various documents, for example, WO2019183438A1 discloses a method for preparing the present rituximab using MMAE, and WO 2017/025057 Al describes a method for preparing polypeptide drug conjugate drugs using MMAE. The disclosures of these documents are incorporated herein by reference.
The invention provides a new crystal form of monomethyl auristatin E and a preparation method thereof, the crystal form has high purity, good stability and low hygroscopicity, is particularly suitable for industrial application, and overcomes the defects of low purity, poor stability, unsuitability for storage, high requirement on reaction equipment, complex operation and the like when amorphous MMAE is used for preparing a conjugate in the prior art; secondly, the preparation method of the MMAE crystal form A provided by the invention is simple to operate, the prepared crystal form is high in purity and uniform in particle size distribution, the production cost is reduced, and the method is suitable for commercial production amplification, and the purity of the MMAE can be improved to more than 99.5%.
The MMAE and the monomethyl auristatin E have the same meanings, and all refer to compounds with the structures shown in the formula (I):
the term "w/w" as used herein means a weight ratio unless otherwise specified.
Drawings
The technical solution of the present application is further explained below with reference to the drawings and the embodiments.
Figure 1 is an X-ray powder diffraction (XRPD) pattern of form a of the compound of formula (I) prepared in example 2;
figure 2 XRPD pattern of form a of the compound of formula (I) prepared in example 3;
FIG. 3 is a DSC of form A of the compound of formula (I);
FIG. 4 is a TGA profile of crystalline form A of the compound of formula (I);
FIG. 5 is an HPLC plot of form A of the compound of formula (I);
FIG. 6 is an XRPD pattern for commercially available sample 1;
FIG. 7 is an XRPD pattern for commercially available sample 2;
FIG. 8 is an XRPD pattern for commercially available sample 3;
FIG. 9 is an HPLC chart of commercial sample 1;
FIG. 10 is an HPLC chart of commercial sample 2;
FIG. 11 is an HPLC chart of commercially available sample 3.
Detailed Description
The present invention will be described in further detail with reference to specific examples, but the present invention is not limited to the following examples; it should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. Conditions not indicated in the examples are conventional experimental conditions. The starting material (i.e. MMAE) used in the present invention is an amorphous white powder obtained commercially or synthesized by a synthetic route known in the art, for example, from CN 109200291A.
The moisture content, unless otherwise specified, was calculated by coulometry.
The seed crystals used in examples 2 to 6 below were crystals A prepared by the method of example 1.
Example 1 preparation of crystalline form A of Monomethylauristatin E
Adding ethyl acetate (2.6 mL) into methyl auristatin E (0.65g, HPLC.
Example 2 preparation of Monomethylauristatin E form A
Adding ethyl acetate (2.6 mL) into methyl auristatin E (0.65g, HPLC, 98.8%) and stirring until the ethyl acetate is dissolved, adding purified water (28.0 mg), stirring uniformly, detecting the water content to be 1.03% by a coulometry method, adding seed crystals (25.0 mg), cooling to 2.5 ℃, stirring for 15-20 h, precipitating a large amount of solid, dropwise adding methyl tert-butyl ether (2.6 mL), stirring for 1-2 h, dropwise adding n-heptane (13.0 mL), continuously stirring for 2-4 h, filtering, leaching the solid with n-heptane (0.6 mL), and drying in vacuum at 40 ℃ to obtain a methyl auristatin E crystal, HPLC:99.4 percent.
Example 3 preparation of Monomethylauristatin E form A
Adding isopropyl acetate (4.0 mL) into methyl auristatin E (1.00g, HPLC (high performance liquid chromatography): 99.5 percent.
Example 4 preparation of Monomethylauristatin E form A
Adding a mixture (4.0 mL) of ethyl acetate and propyl acetate into methyl auristatin E (1.00g, HPLC (high performance liquid chromatography).
Example 5 preparation of crystalline form A of Monomethylauristatin E
Adding butyl acetate (3.0 mL) into monomethyl auristatin E (1.00g, HPLC, 94.9%) and stirring until the mixture is dissolved, adding purified water (51.1 mg) and stirring uniformly, detecting the water content to be 2% by using a coulometry method, adding seed crystals (40.0 mg), cooling to 2.5 ℃, stirring for 15-20 h, precipitating a large amount of solid, adding methyl tert-butyl ether (6.0 mL) dropwise, stirring for 1-2 h, adding n-heptane (15.0 mL), continuing stirring for 2-4 h, filtering, leaching the solid with n-heptane (1.0 mL), and drying in vacuum at 40 ℃ to obtain monomethyl auristatin E crystals.
Example 6 preparation of Monomethylauristatin E form A
Methyl formate (4.0 mL) is added into monomethyl auristatin E (1.00g, HPLC.
X-ray powder diffraction analysis (XRP D) was performed on the samples prepared in examples 2 to 6; and the sample prepared in example 2 was subjected to Differential Scanning Calorimetry (DSC) and simultaneous thermal analysis (TGA), in which,
x-ray powder diffraction analysis (XRPD) was collected on Bruker D8 ADVANCE, cuka radiation. The method parameters are as follows:
a test mode: wide angle;
scanning range: 2-50 °;
step length of test: 0.01 degree/step;
integration time: 0.1 s/step.
XRPD tests show that the samples 1 to 6 prepared in the examples 1 to 6 are all crystals and are named as the crystal form A.
The XRPD pattern of the MMAE crystalline form prepared in example 2 is shown in fig. 1, wherein a total of 39 peaks are shown, the specific diffraction data are shown in table 1, and the 2theta values are determined by considering various factors such as d value, low angle, intensity, characteristic line and complete peak shape, and the diffraction peaks at the positions of 3.8 ° ± 0.2 °, 9.3 ° ± 0.2 °, 9.9 ° ± 0.2 ° and 13.2 ° ± 0.2 ° are characteristic peaks. Diffraction peaks at 2theta values of 10.8 ° ± 0.2 °, 11.9 ° ± 0.2 °, 15.3 ° ± 0.2 ° and 16.3 ° ± 0.2 ° are important peaks. The diffraction peaks at 2theta values of 15.1 DEG +/-0.2 DEG, 18.4 DEG +/-0.2 DEG, 18.6 DEG +/-0.2 DEG, 20.1 DEG +/-0.2 DEG, 21.6 DEG +/-0.2 DEG and 23.0 DEG +/-0.2 DEG are the secondary important peaks.
TABLE 1
The XRPD pattern of the MMAE crystalline form prepared in example 3 is shown in fig. 2, the specific diffraction data is determined by considering various factors such as d value, low angle, intensity, characteristic line and complete peak shape, referring to table 2, the 2theta value is 3.8 ° ± 0.2 °, 9.3 ° ± 0.2 °, 9.9 ° ± 0.2 ° and the diffraction peak at 13.2 ° ± 0.2 ° is the characteristic peak. Diffraction peaks at 2theta values of 10.8 ° ± 0.2 °, 11.9 ° ± 0.2 °, 15.3 ° ± 0.2 ° and 16.3 ° ± 0.2 ° are important peaks. The diffraction peaks at 2theta values of 15.1 DEG +/-0.2 DEG, 18.4 DEG +/-0.2 DEG, 18.6 DEG +/-0.2 DEG, 20.1 DEG +/-0.2 DEG, 21.6 DEG +/-0.2 DEG and 23.0 DEG +/-0.2 DEG are the secondary important peaks.
TABLE 2
The XRPD patterns of the MMAE crystalline forms prepared in examples 4-6 are essentially the same as shown in fig. 1-2.
The Differential Scanning Calorimetry (DSC) chart of the invention is collected on a TADICOMOVERY DSC25, and the method parameters are as follows:
sample pan: aluminum plate and gland
Temperature range: 25-268 deg.C
Scanning speed: 10 ℃/min
Protective gas: and (4) nitrogen.
A DSC diagram as shown in figure 3, showing that form a prepared in example 2 shows an endothermic peak at 112.81 ℃.
Simultaneous thermal analysis (TGA) plots were collected on METTLER TGA/DSC3+/1100F with the following process parameters:
sample pan: alumina oxide
Temperature range: 25-550 deg.C
Scanning rate: 10 ℃/min
Protective gas: nitrogen gas
A TGA profile as shown in figure 4, wherein form a prepared in example 2 is shown to begin with a weight loss at about 305 ℃.
Example 7 hygroscopicity test
Respectively measuring the moisture content of the MMAE crystal form prepared in the embodiment 2 of the invention and 500mg of the purchased amorphous MMAE, and recording the moisture content as the moisture content of the initial condition; then, the sample was placed at 25 ℃ and humidity of 92.5% for 24 hours, and then the moisture content was measured by coulometry, and the measurement results are shown in Table 3.
TABLE 3, 25 ℃,92.5% humidity examination results
Example 8 MMAE form a versus amorphous MMAE solubility contrast test
Comparing the solubility of the MMAE crystal form A prepared in the embodiment 2 of the invention with that of amorphous MMAE; the MMAE crystal form A and amorphous MMAE prepared in the embodiment 2 of the invention are respectively added into methyl tert-butyl ether at 20-25 ℃ to prepare saturated solution, and then the content of the MMAE in the saturated solution is determined by a high performance liquid chromatography after 1 hour and 2 hours. The results of the experiment are shown in table 4.
TABLE 4 solubility contrast test results for MMAE form A and amorphous MMAE
Example 9 stability study of MMAE form A
The MMAE crystal form A prepared in the embodiment 2 of the invention is placed at 40 ℃, and the purity and the moisture are respectively detected by a high performance liquid chromatography and a coulometry method in 1 month and 2 months. The results of the experiment are shown in Table 5.
TABLE 5 stability study results of MMAE form A
Time | Purity of | Moisture content |
Initiation of | 99.42% | 2.7% |
1 month | 99.45% | 2.2% |
2 months old | 99.42% | 2.2% |
Example 10 comparison of MMAE form A to MMAE amorphous purity
The MMAE solid prepared in example 2 of the present invention and the crystal form of the sample purchased from 3 different manufacturers were tested by XRPD and the purity of the sample was determined by HPLC method, the results are shown in table 6.
TABLE 6 comparison of amorphous purity of MMAE crystal form A and MMAE
The MMAE crystal forms prepared in examples 3-6 and the MMAE crystal form prepared in example 2 have similar properties in stability, solubility, and hygroscopicity, and the purity is also improved to different degrees compared to amorphous powder.
In light of the foregoing description of the preferred embodiments according to the present application, it is to be understood that various changes and modifications may be made without departing from the spirit and scope of the invention. The technical scope of the present application is not limited to the contents of the specification, and must be determined according to the scope of the claims.
Claims (28)
2. form a of the compound of formula (I) according to claim 1, characterized in that it has an X-ray powder diffraction pattern at 2 Θ values: diffraction peaks are present at positions of 3.8 degrees +/-0.2 degrees, 9.3 degrees +/-0.2 degrees, 9.9 degrees +/-0.2 degrees, 10.8 degrees +/-0.2 degrees, 11.9 degrees +/-0.2 degrees, 13.2 degrees +/-0.2 degrees, 15.1 degrees +/-0.2 degrees, 15.3 degrees +/-0.2 degrees, 16.3 degrees +/-0.2 degrees, 18.4 degrees +/-0.2 degrees, 18.6 degrees +/-0.2 degrees, 20.1 degrees +/-0.2 degrees, 21.6 degrees +/-0.2 degrees and 23.0 degrees +/-0.2 degrees.
3. Form a of the compound of formula (I) according to claim 1, characterized in that it has substantially the same X-ray powder diffraction pattern as shown in figure 1 or figure 2.
4. Form A of the compound of formula (I) according to claim 1 or 2, characterized in that its Differential Scanning Calorimetry (DSC) pattern comprises an endothermic peak at 112.81 ℃ ± 2 ℃.
5. Form a of the compound of formula (I) according to claim 1 or 2, characterized in that it has a DSC profile substantially the same as shown in figure 3.
6. Form a of the compound of formula (I) according to claim 1 or 2, characterized in that it contains 0-5% (w/w) water.
7. Form A of the compound of formula (I) according to claim 6, characterized in that it contains 1-3%
(w/w) water.
8. A process for the preparation of crystalline form a of the compound of formula (I) according to any one of claims 1 to 7, comprising the steps of:
a) Adding a compound shown in a formula (I) into a first solvent, stirring and dissolving to obtain a first mixed system, wherein the first solvent is ethyl acetate;
b) Stirring the first mixed system, and then adding a second solvent into the first mixed system to obtain a second mixed system, wherein the second solvent is methyl tert-butyl ether;
c) Stirring the second mixed system, and then adding a third solvent into the second mixed system to obtain a third mixed system, wherein the third solvent is n-heptane;
d) And stirring the third mixed system to separate out a solid, thus obtaining the catalyst.
9. A process for the preparation of crystalline form a of the compound of formula (I) according to any one of claims 1 to 7, comprising the steps of:
a) Adding a compound shown in a formula (I) into a first solvent, stirring and dissolving to obtain a first mixed system, wherein the first solvent is selected from methyl formate, ethyl acetate, isopropyl acetate, butyl acetate or a mixed solution of ethyl acetate and propyl acetate;
b) Stirring the first mixed system, adding crystal seeds of a crystal form A of the compound shown in the formula (I), and adding a second solvent to obtain a second mixed system, wherein the second solvent is methyl tert-butyl ether;
c) Stirring the second mixed system, and then adding a third solvent into the second mixed system to obtain a third mixed system, wherein the third solvent is n-heptane;
d) And stirring the third mixed system to separate out solids to obtain the catalyst.
10. The method according to claim 8 or 9, wherein the compound represented by the formula (I) is added to the first solvent, dissolved with stirring, and added with water to obtain the first mixed system.
11. The method according to claim 8 or 9, wherein the stirring of the first mixed system in the step B) is performed at a temperature of-10 to 10 ℃;
the stirring second mixed system in the step C) is stirred at the temperature of-10 ℃;
and D), stirring the third mixed system at the temperature of-10 ℃.
12. The method according to claim 10, wherein the amount of water in step a) is 0.5% to 4% (w/w) based on the total amount of the first mixed system.
13. The method as set forth in claim 12, wherein the amount of water in step a) is 1% to 2% (w/w) based on the total amount of the first mixed system.
14. The method according to claim 12, wherein step a) is carried out in a water content of 1-1.5% (w/w) based on the total amount of the first mixed system.
15. The method according to claim 8 or 9, wherein the volume ratio of the first solvent to the second solvent to the third solvent is 1.
16. The method according to claim 15, wherein the volume ratio of the first solvent to the second solvent to the third solvent is 1.
17. The method according to claim 15, wherein the volume ratio of the first solvent to the second solvent to the third solvent is 1.
18. The method according to claim 8 or 9, wherein the dosage ratio of the compound of formula (I) to the first solvent is 1.
19. The method according to claim 18, wherein the ratio of the weight of the compound represented by formula (I) to the volume of the first solvent is 1.
20. The method as claimed in claim 9, wherein the step B) is carried out by stirring the first mixed system, adding the seed crystal, cooling to-10 to 10 ℃, and adding the second solvent to obtain the second mixed system.
21. A pharmaceutical composition comprising the crystalline form a of the compound of formula (I) according to any one of claims 1 to 7 and a pharmaceutically acceptable carrier.
22. The pharmaceutical composition according to claim 21, wherein the composition contains not less than 85% by weight of the compound of formula (I) in form a of the crystalline form a according to claim 1, relative to the total amount of the compound of formula (I) present in the composition.
23. The pharmaceutical composition according to claim 22, wherein the composition comprises not less than 90% by weight of the compound of formula (I) in form a according to claim 1.
24. Pharmaceutical composition according to claim 22, characterized in that it contains not less than 95% by weight of the compound of formula (I) in form a according to claim 1.
25. The pharmaceutical composition according to claim 22, wherein the composition comprises not less than 99% by weight of the compound of formula (I) in form a according to claim 1.
26. The pharmaceutical composition according to claim 22, wherein the composition comprises not less than 99.5% by weight of the compound of formula (I) in form a according to claim 1.
27. The pharmaceutical composition according to claim 22, wherein the composition comprises not less than 99.9% by weight of the compound of formula (I) in form a according to claim 1.
28. Use of crystalline form a of a compound of formula (I) according to any one of claims 1 to 7 for the preparation of a pharmaceutical conjugate.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110239973.0A CN113121640B (en) | 2021-03-04 | 2021-03-04 | Crystal of monomethyl auristatin E and preparation method thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110239973.0A CN113121640B (en) | 2021-03-04 | 2021-03-04 | Crystal of monomethyl auristatin E and preparation method thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113121640A CN113121640A (en) | 2021-07-16 |
CN113121640B true CN113121640B (en) | 2022-10-28 |
Family
ID=76772771
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110239973.0A Active CN113121640B (en) | 2021-03-04 | 2021-03-04 | Crystal of monomethyl auristatin E and preparation method thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113121640B (en) |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10596259B2 (en) * | 2015-05-20 | 2020-03-24 | The Regents Of The University Of California | Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof |
CN105175422B (en) * | 2015-09-18 | 2018-04-20 | 深圳市海滨制药有限公司 | A kind of phosphoric acid Xi Gelieting crystal and its preparation method and application |
CN105837516B (en) * | 2016-05-16 | 2018-07-10 | 山东新时代药业有限公司 | A kind of rosuvastain calcium crystal form and preparation method thereof |
CN108383845B (en) * | 2018-04-26 | 2020-11-06 | 盛世泰科生物医药技术(苏州)有限公司 | Crystal form and amorphous form of Shenggliptin salt, preparation method and application thereof |
CN111896648A (en) * | 2020-07-23 | 2020-11-06 | 苏州宜百奥生物科技有限公司 | Method for analyzing and preparing MMAE chiral isomer by high performance liquid chromatography |
-
2021
- 2021-03-04 CN CN202110239973.0A patent/CN113121640B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN113121640A (en) | 2021-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017107972A1 (en) | Novel crystalline form of selective s1p1 receptor agonist and method for preparing same | |
AU2017336889B2 (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
CN107652342A (en) | Polymorphic of nucleoside phosphoramidate class prodrug and preparation method thereof | |
CN113121640B (en) | Crystal of monomethyl auristatin E and preparation method thereof | |
WO2020186960A1 (en) | Bulleyaconitine a crystalline form c, preparation method therefor and application thereof | |
CN114195693A (en) | Crystal form of amide compound and preparation method thereof | |
CN110156793B (en) | Novel crystal form of Ribociclib monosuccinate and preparation method thereof | |
WO2020186963A1 (en) | Crystal form g of bulleyaconitine a, preparation method therefor and application thereof | |
CN109134502A (en) | A kind of 1/2 water cefuroxime sodium compound | |
CN114057643B (en) | Rosemastat eutectic crystal and preparation method thereof | |
WO2018214877A1 (en) | Crystal form of dezocine and preparation method therefor | |
TWI801759B (en) | Hexadecyl treprostinil crystals and methods for preparation thereof | |
WO2017028762A1 (en) | Crystal form of naphthalene cyclic compound | |
CN110372635B (en) | Preparation method of vortioxetine hydrobromide alpha crystal form | |
CA2571645A1 (en) | Pharmaceutically acceptable salts of thymodepressin and processes for their manufacture | |
CN112961107A (en) | Crystal form of roxasistat and preparation method thereof | |
CN109134501A (en) | 1/5 water cefradine compound of one kind and its drug combination preparation | |
CN113336741A (en) | Rabeprazole sodium anhydrate crystal form and preparation method thereof | |
CN107663166A (en) | Lome Tapai and its production and use | |
KR20170060035A (en) | L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of l-proline compound | |
WO2019037591A1 (en) | Melphalan hydrochloride crystal form, preparation method therefor and application thereof | |
CN117003702B (en) | Fluocytosine-orotate and preparation method and application thereof | |
CN112625016B (en) | 7-Hydroxy butylphthalide crystal form B and preparation method thereof | |
CN116854694B (en) | Crystal forms of [1,2,4] triazole [4,3-b ] pyridazine compound, and preparation method and application thereof | |
WO2015078382A1 (en) | Endo-(14s)-3-methoxy-17-methylmorphinan picrate and preparation method and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20210716 Assignee: Tongyi Pharmaceutical (Hefei) Co.,Ltd. Assignor: Tong Yi medicine (Suzhou) Co.,Ltd. Contract record no.: X2024980000028 Denomination of invention: A Crystal and Preparation Method of Methyl Aurestatin E Granted publication date: 20221028 License type: Common License Record date: 20240104 |